ESR1 and breast cancer: Endocrine therapy, in turn, can alter tumor expression of ER and PR [5,6]; in particular, upon acquiring resistance to an endocrine agent such as tamoxifen, metastatic breast cancers usually retain ER expression [5] but frequently exhibit loss of PR expression [6].